147 related articles for article (PubMed ID: 15342407)
1. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T
Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.
Pakunlu RI; Cook TJ; Minko T
Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953
[TBL] [Abstract][Full Text] [Related]
3. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug.
Wang Y; Minko T
Biochem Pharmacol; 2004 Nov; 68(10):2031-42. PubMed ID: 15476674
[TBL] [Abstract][Full Text] [Related]
4. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Lo YL; Liu Y
PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
Shinoda C; Maruyama M; Fujishita T; Dohkan J; Oda H; Shinoda K; Yamada T; Miyabayashi K; Hayashi R; Kawagishi Y; Fujita T; Matsui S; Sugiyama E; Muraguchi A; Kobayashi M
Int J Cancer; 2005 Oct; 117(1):21-31. PubMed ID: 15880572
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
[TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy.
Dharap SS; Chandna P; Wang Y; Khandare JJ; Qiu B; Stein S; Minko T
J Pharmacol Exp Ther; 2006 Mar; 316(3):992-8. PubMed ID: 16291730
[TBL] [Abstract][Full Text] [Related]
10. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
Wang Y; Saad M; Pakunlu RI; Khandare JJ; Garbuzenko OB; Vetcher AA; Soldatenkov VA; Pozharov VP; Minko T
Clin Cancer Res; 2008 Jun; 14(11):3607-16. PubMed ID: 18519795
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
Saad M; Garbuzenko OB; Minko T
Nanomedicine (Lond); 2008 Dec; 3(6):761-76. PubMed ID: 19025451
[TBL] [Abstract][Full Text] [Related]
12. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
13. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
Sartorius UA; Krammer PH
Int J Cancer; 2002 Feb; 97(5):584-92. PubMed ID: 11807782
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance.
Garbuzenko OB; Saad M; Pozharov VP; Reuhl KR; Mainelis G; Minko T
Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10737-42. PubMed ID: 20498076
[TBL] [Abstract][Full Text] [Related]
16. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.
Young LC; Campling BG; Cole SP; Deeley RG; Gerlach JH
Clin Cancer Res; 2001 Jun; 7(6):1798-804. PubMed ID: 11410522
[TBL] [Abstract][Full Text] [Related]
18. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
Taratula O; Garbuzenko OB; Chen AM; Minko T
J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
Loriot Y; Mordant P; Brown BD; Bourhis J; Soria JC; Deutsch E
Anticancer Res; 2010 Oct; 30(10):3869-78. PubMed ID: 21036697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]